Join

Compare · ELV vs EXAS

ELV vs EXAS

Side-by-side comparison of Elevance Health Inc. (ELV) and Exact Sciences Corporation (EXAS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ELV and EXAS operate in Medical Specialities (Health Care), so they compete in similar markets.
  • ELV is the larger of the two at $84.97B, about 7.0x EXAS ($12.19B).
  • Over the past year, ELV is up 3.3% and EXAS is up 91.4% - EXAS leads by 88.1 points.
  • ELV has hit the wire 13 times in the past 4 weeks while EXAS has been quiet.
  • EXAS has more recent analyst coverage (25 ratings vs 23 for ELV).
PerformanceELV+26.39%EXAS+91.39%
2025-08-15+0.00%2026-06-03
MetricELVEXAS
Company
Elevance Health Inc.
Exact Sciences Corporation
Price
$391.27+0.64%
$104.94+1.02%
Market cap
$84.97B
$12.19B
1M return
+5.19%
+1.60%
1Y return
+3.29%
+91.39%
Industry
Medical Specialities
Medical Specialities
Exchange
NYSE
NASDAQ
IPO
2001
News (4w)
13
0
Recent ratings
23
25
ELV

Elevance Health Inc.

Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

EXAS

Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Latest ELV

Latest EXAS